Thus, the augmented GD3 in CTCL lesions is considered to, at least, partially suppress IL-17A production from the benign CD4 T cells, possibly via siglec-7, which is dominantly expressed in CD103 fraction. Here, CD4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.